Anti-IL1RA antibody [A71B6D11] (Biotin) (ab25074)
- Product nameAnti-IL1RA antibody [A71B6D11] (Biotin)See all IL1RA primary antibodies ...
- DescriptionMouse monoclonal [A71B6D11] to IL1RA (Biotin)
- SpecificityRecognises natural and recombinant IL1RA.
- Tested applicationsELISA more details
- Species reactivityReacts with: Human
Recombinant human IL1RA
- Storage instructionsStore at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
- Storage bufferPreservative: 0.05% Sodium Azide
Constituents: 0.5% BSA, 0.1M PBS, pH 7.5
- Concentration information loading...
- PurityProtein A purified
- Clonality Monoclonal
- Clone numberA71B6D11
- Research Areas
Our Abpromise guarantee covers the use of ab25074 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||ELISA: Use a concentration of 0.1 - 1 µg/ml.|
- FunctionInhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure.
- Tissue specificityThe intracellular form of IL1RN is predominantly expressed in epithelial cells.
- Involvement in diseaseGenetic variation in IL1RN is associated with susceptibility to microvascular complications of diabetes type 4 (MVCD4) [MIM:612628]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
Defects in IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]; also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis (bone inflammation in multiple places), periostitis (inflammation of the membrane surrounding the bones), and pustulosis (due to skin inflammation) from birth.
- Cellular localizationCytoplasm and Secreted.
- DIRA antibody
- ICIL 1RA antibody
- ICIL-1RA antibody
- ICIL1RA antibody
- IL-1ra antibody
- IL-1ra3 antibody
- IL-1RN antibody
- IL1 inhibitor antibody
- IL1F3 antibody
- IL1RA antibody
- IL1RA_HUMAN antibody
- IL1RN (IL1F3) antibody
- IL1RN antibody
- Interleukin 1 receptor antagonist antibody
- Interleukin 1 Receptor Antagonist Protein antibody
- Interleukin-1 receptor antagonist protein antibody
- Intracellular IL 1 receptor antagonist type II antibody
- Intracellular interleukin 1 receptor antagonist (icIL 1ra) antibody
- IRAP antibody
- MGC10430 antibody
- MVCD4 antibody
- Type II interleukin 1 receptor antagonist antibody
References for Anti-IL1RA antibody [A71B6D11] (Biotin) (ab25074)
ab25074 has not yet been referenced specifically in any publications.